Workplace Drug Screening Is Not the Same as Clinical Toxicology
Drug screening labs serve two very different worlds. On one side, clinical toxicology labs run broad pain management panels and medication reconciliation for physician offices. On the other, workplace drug screening labs handle pre-employment testing, random employee testing, post-accident testing, and DOT-mandated panels for transportation workers.
The workflows, regulatory requirements, and reporting standards for these two worlds barely overlap. A clinical toxicology panel might test for dozens of prescribed medications and their metabolites. A DOT workplace screen follows a rigid 5-panel protocol defined by SAMHSA (the Substance Abuse and Mental Health Services Administration) that tests specifically for amphetamines, THC, cocaine, opiates, and PCP.
The problem is that many laboratory information systems were designed for one side or the other, not both. If your lab handles workplace screening, your LIS needs to understand DOT/SAMHSA rules, enforce the correct cutoff levels, manage specimen validity testing, and produce results that hold up under legal scrutiny.
DOT and SAMHSA Panel Requirements
SAMHSA sets the standard for federal workplace drug testing, and DOT enforces those standards for safety-sensitive transportation workers. The standard SAMHSA 5-panel tests for five drug classes, but many employers also request expanded panels (7-panel, 10-panel, or 12-panel) that add benzodiazepines, barbiturates, methadone, propoxyphene, or methaqualone.
Each panel has specific cutoff concentrations for both the initial immunoassay screen and the LC-MS/MS confirmation. For example, the initial immunoassay screen cutoff for amphetamines is 500 ng/mL, but the confirmation cutoff for methamphetamine drops to 250 ng/mL. These cutoff levels are not suggestions. They are regulatory requirements, and applying the wrong cutoff to a workplace test can invalidate the result entirely.
Your LIS needs to store and enforce these per-analyte cutoff levels automatically. When a lab technician runs a confirmation on a positive screen, the system should already know which cutoff applies based on the panel type, the analyte in question, and whether the test falls under DOT or non-DOT rules. Manual lookup of cutoff tables introduces errors that no drug screening lab can afford.
Two-Tier Testing: Screen and Confirm
Workplace drug screening follows a strict two-tier process. The initial screen uses immunoassay technology to quickly categorize a specimen as negative or presumptive positive for each drug class. Specimens that screen positive must then be confirmed using a more specific method, typically LC-MS/MS (liquid chromatography-tandem mass spectrometry), which identifies and quantifies the exact substance present.
This matters because immunoassay screens can produce cross-reactive results. An over-the-counter cold medication containing pseudoephedrine might trigger a presumptive positive for amphetamines on the initial screen. The LC-MS/MS confirmation resolves that by distinguishing pseudoephedrine from actual methamphetamine.
An LIS built for drug screening should handle the automatic reflex from screen to confirmation. When the immunoassay result crosses the screen cutoff threshold, the system should generate the confirmation order, track the specimen through the confirmation process, and apply the correct confirmation cutoff without manual intervention. This automated reflex prevents specimens from falling through the cracks between screening and confirmation.
Specimen Validity Testing
Before any drug result means anything, the lab must verify that the specimen itself is valid. Specimen validity testing (SVT) checks for substitution, dilution, and adulteration by measuring creatinine concentration, pH, specific gravity, and oxidizing adulterants.
A specimen with a creatinine level below 2 mg/dL and a specific gravity below 1.0010 or above 1.0200 is reported as substituted. A creatinine between 2 and 20 mg/dL with a specific gravity between 1.0010 and 1.0030 is reported as dilute. A pH below 3.0 or above 11.0 indicates adulteration.
These thresholds need to be built into the LIS so that validity results are automatically evaluated and flagged. If a specimen is reported as substituted, the drug test results should not be released without appropriate review. The LIS should prevent a tech from accidentally reporting drug results on an invalid specimen.
Chain of Custody for Forensic Defensibility
Workplace drug test results often end up in legal proceedings. An employee who tests positive may challenge the result, and the lab needs to prove an unbroken chain of custody from the moment the specimen was collected to the moment the result was reported.
This means every hand-off must be documented: who collected the specimen, when it arrived at the lab, who accessioned it, who performed the screen, who performed the confirmation, and who reviewed and released the result. Paper-based chain of custody forms are still common, but they create gaps. Handwriting is misread, forms are misfiled, timestamps are inconsistent.
An electronic chain of custody within the LIS replaces disconnected handoffs with attributable records. Each custody transfer can retain its timestamp, user, and location, while record edits, result changes, and approvals remain in a tamper-evident event history. A chain-of-custody report then gives a Medical Review Officer (MRO) or other reviewer one place to examine the documented sequence without promising that software alone eliminates every process gap.
The MRO Workflow
For DOT-regulated testing, results do not go directly from the lab to the employer. They go to a Medical Review Officer, a licensed physician trained to evaluate drug test results. The MRO reviews positive results, contacts the donor to determine whether a legitimate medical explanation exists (such as a valid prescription), and then reports the final result to the employer.
The LIS needs to support this workflow by routing positive results to the MRO, tracking the MRO review status, and recording the MRO’s final determination. When an MRO downgrades a positive to a negative based on a verified prescription, that decision and its rationale should be captured in the system.
How LIMS IQ Handles Drug Screening
LIMS IQ supports configurable screening and confirmation tests, analyte limits, and orderable panels for toxicology workflows. Lab-defined reflex rules can route a specimen to confirmation when a screening result meets the configured cutoff, while screening and confirmation results can be compared for consistency during review.
Instrument interfaces can bring immunoassay and LC-MS/MS results into the review workspace, and the dedicated toxicology batch view presents screening and confirmation results side by side. Specimens that fail the lab’s configured validity checks move through a dedicated validity-rejection workflow instead of being described as automatically meeting a universal regulatory rule set.
Electronic custody logs record specimen transfers with timestamps, users, and locations, and the audit history retains edits, result changes, and approvals. Chain-of-custody reports make that recorded history available for internal QA, compliance review, or legal documentation.
Labs that handle both workplace screening and clinical toxicology can configure their panels, cutoffs, reflex rules, reports, and review steps in the same platform. The exact DOT or SAMHSA panel definitions, MRO procedure, analyzer connection, and reporting rules still need to be scoped and validated against the lab’s current SOPs and trading partners.
For the broader evaluation — chain of custody, screening-to-confirmation workflows, medication consistency, reporting, integrations, and billing — see the LIMS for toxicology labs buyer’s guide.
Schedule a demo to review how LIMS IQ handles screening, confirmation, validity review, and chain-of-custody records for your lab’s configured workflow.